Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101930 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular Effects of GLP-1 Receptor Activation
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 329
- Enrollment target
NCT03101930 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 329 participants.
The verdict
NCT03101930, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 329 participants
- Enrollment target
Study Summary
This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.
Interventions
- DRUG Sitagliptin
- DRUG Placebos
- DRUG Liraglutide
- DRUG Exendin (9-39)
- OTHER hypocaloric diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03101930
The ClinicalTrials.gov registry entry for NCT03101930 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sitagliptin is the first listed.
NCT03101930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03101930 about?
NCT03101930 is a clinical study titled "Cardiovascular Effects of GLP-1 Receptor Activation". This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual ...
What is the current status of trial NCT03101930?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 329 participants. The study started on 2017-05-01. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03101930?
The interventions under investigation include: Sitagliptin (DRUG), Placebos (DRUG), Liraglutide (DRUG), Exendin (9-39) (DRUG), hypocaloric diet (OTHER).
Who is sponsoring clinical trial NCT03101930?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.